SCHEMBL5396289

SCHEMBL5396289

CC(C)c1nsc(NS(=O)(=O)c2c(F)cccc2F)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.42
SLC40A1 Q9NP59 2/20 0.42
BRAF P15056 5/20 0.40
SCN1A P35498 5/20 0.40
SCN5A Q14524 5/20 0.40
SCN8A Q9UQD0 5/20 0.40
PKM P14618 1/20 0.40
NR1I2 O75469 3/20 0.38
CYP2C9 P11712 2/20 0.38
SCN1B Q07699 2/20 0.38
SCN2A Q99250 2/20 0.38
BRD4 O60885 2/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
EIF2AK3 Q9NZJ5 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5395852 0.84 SCN9A (0.42) SCN9ASLC40A1PKM
SCHEMBL5386367 0.81 SCN9A (0.49) SCN9ABRAFPIK3CA
SCHEMBL5391600 0.80 SCN9A (0.50) SCN9APKM
SCHEMBL5401411 0.78 POLB (0.44) SCN9ASCN1ASCN5ASCN8ANR1I2
SCHEMBL5391581 0.77 MEN1 (0.42) SCN9ACYP3A4TP53
SCHEMBL5389363 0.77 SCN9A (0.41) SCN9ASLC40A1SCN1ASCN5ASCN8A
SCHEMBL5392421 0.76 HCRTR1 (0.48) SCN9ABRD4
SCHEMBL5391554 0.76 SCN9A (0.48) SCN9ASCN1ASCN5ASCN8APKM
SCHEMBL5401349 0.76 NPC1 (0.52) PKMTP53
SCHEMBL5404427 0.75 MEN1 (0.54) SCN9ASLC40A1SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 SCN9A 1476/4885SLC40A1 2401/4885BRAF 4250/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 SCN9A 1829/4885SLC40A1 2376/4885BRAF 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.